Search tips
Search criteria 


Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
Sci Rep. 2017; 7: 45954.
Published online 2017 April 6. doi:  10.1038/srep45954
PMCID: PMC5382685

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells


Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and succumb to chemoresistant disease. Overcoming drug resistance is the key to successful treatment of EOC. Members of vascular endothelial growth factor (VEGF) family are overexpressed in EOC and play key roles in its malignant progression though their contribution in development of the chemoresistant disease remains elusive. Here we show that expression of the VEGF family is higher in therapy-resistant EOC cells compared to sensitive ones. Overexpression of VEGFR2 correlated with resistance to cisplatin and combination with VEGFR2-inhibitor apatinib synergistically increased cisplatin sensitivity. Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. Tivozanib decreased invasive potential of these cells, concomitant with reduction of intercellular adhesion molecule-1 (ICAM-1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2). Moreover, tivozanib synergistically enhanced anti-tumour effects of EGFR-directed therapies including erlotinib. These findings suggest that the VEGF pathway has potential as a therapeutic target in therapy-resistant EOC and VEGFR blockade by tivozanib may yield stronger anti-tumour efficacy and circumvent resistance to EGFR-directed therapies.

Epithelial ovarian cancer (EOC) is the fifth most common cause of cancer death among women worldwide. It is estimated that approximately 22000 women are diagnosed with EOC in the United States and 14000 patients die from this disease each year1. Late-stage diagnosis, peritoneal metastasis and frequent development of chemoresistance restrain improvements in overall survival rate. First-line treatment for EOC includes debulking surgery followed by taxane/platinum-based regimens. Despite promising initial response, the majority of patients with advanced disease relapse and exhibit resistance to both chemotherapeutics and targeted therapies2.

Intrinsic and acquired resistance to chemotherapy are responsible for treatment failure in EOC3. Patients with the recurrent disease are treated with agents such as gemcitabine but clinical trials report that the median overall survival is still dismal4. There is, therefore, a pressing need to devise more efficacious treatments to overcome chemoresistance mechanisms and improve the outcome of EOC patients.

Angiogenesis, a multi-step process by which tumours develop new vasculature, is essential for tumour growth and metastasis5. The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signalling pathway is the most promising angiogenic target due to its key roles in angiogenesis and tumour growth6,7. The VEGF family consists of seven ligands including VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, placenta growth factor (PlGF) 1, and PlGF2. The tyrosine kinase receptors in this family include VEGFR type 1 (VEGFR1), VEGFR2 and VEGFR36. Synthesized VEGF mimicking peptides have also been shown to bind to VEGF receptors, initiate VEGF-induced signalling and stimulate angiogenesis8.

Elevated expression of the VEGF ligands and receptors promotes malignant progression and correlates with poor prognosis in EOC9,10. High expression of VEGFA associates with advanced stage disease, development of malignant ascites and acquisition of an invasive phenotype11. Increased expression of VEGFC and VEGFR2 correlates with lymph node metastasis and peritoneal dissemination, a frequent cause of death in patients with primary advanced or recurrent EOC12,13. In this setting, blocking VEGFA activity in murine models of EOC halts tumour growth and ascites formation14. Altogether, these studies suggest that the VEGF family is importantly implicated in pathogenesis of EOC by influencing tumour growth and metastasis (via driving angiogenesis) and ascites formation (through stimulation of vascular permeability)15.

Evidence indicates that targeting angiogenesis is an effective therapeutic strategy in EOC and anti-angiogenic agents are among the most successful targeted therapies in this malignancy16,17. Patients treated with bevacizumab (anti-VEGFA mAb) alone or in combination with cytotoxic chemotherapies have demonstrated improvements in progression-free survival18,19. Addition of bevacizumab to several cytotoxic regimens improves response rate in patients with recurrent platinum-resistant disease20,21. While early clinical studies have determined remarkable activity of bevacizumab, lack of improvement in overall survival, considerable toxicity, frequent development of resistance, absence of a predictive biomarker and high cost of bevacizumab therapy highlight the need to establish novel and more efficacious anti-angiogenesis therapy in EOC17,22.

Tivozanib is a pan-VEGFR tyrosine kinase inhibitor that hampers angiogenesis and vascular permeability in tumour tissues23. Tivozanib has shown anti-tumour activities in xenograft models of colon, breast, lung, prostate, pancreas, glioblastoma and renal cell carcinoma24,25. In a phase I study in patients with advanced solid tumours, it has been found to be well tolerable with manageable side effects and durable clinical activity26. Tivozanib is currently under investigation in a phase II study in recurrent platinum-resistant ovarian cancer (NCT01853644)27. In the present study, we examined the mechanistic activity of tivozanib in therapy-resistant EOC cell lines.


Chemosensitivity of the EOC cell lines

The sensitivity of a panel of EOC cell lines to certain chemotherapeutic agents and targeted therapies were determined by MTT assay and are summarized in Table 1. These data show that OVCAR3, SKOV3 and A2780CP cells exhibit multidrug-resistant behaviour. Moreover, A2780S and Caov4 cells show sensitivity to carboplatin, paclitaxel, doxorubicin, gemcitabine, erlotinib and cetuximab (Table 1, Supplementary Fig. 1).

Table 1
Chemosensitivities of a panel of EOC cell lines to certain chemotherapeutics and targeted therapies.

Expression of the VEGF family in the EOC cells

The expression of VEGF ligands and receptors in chemoresistant versus chemosensitive EOC cells is not yet examined. To explore potential association between chemoresponsiveness and expression of the VEGF family, their relative expression was investigated by qRT-PCR. This screening experiment revealed that the expression of VEGFA, VEGFC, VEGFD, VEGFR1 and VEGFR2 is higher in multidrug-resistant OVCAR3, SKOV3 and A2780CP cells compared to the chemosensitive ones (Fig. 1A,B).

Figure 1
Expression of the VEGF family in the EOC cells.

The elevated expression of the VEGF family in the therapy-resistant EOC cells prompted us to examine possible correlation between their mRNA levels and chemoresponsiveness. We found that higher expression of VEGFR2 associates with resistance to cisplatin by Pearson’s correlation (Fig. 1C). The correlation coefficient (r) between the VEGFR2 expression and cisplatin concentrations was 0.8876 (P = 0.0404). To further confirm that VEGFR2 may contribute to cisplatin resistance, we determined the effects of apatinib, a VEGFR2 specific inhibitor, on proliferative response of the chemoresistant EOC cells to cisplatin. For the combination therapy, we followed a time-staggered treatment protocol as described by Lee et al.28. The cells were pre-treated with apatinib for 4 h, followed by treatment with cisplatin for 48 h. Combination with apatinib synergistically increased sensitivity to cisplatin (Fig. 1D–F, Supplementary Table 1).

We also found a positive correlation between erlotinib resistance and higher expression of VEGFC (Fig. 1G). Moreover, pre-treatment with human recombinant VEGFC (10 ng/mL) decreased anti-proliferative effects of erlotinib in the chemosensitive Caov4 cells (Fig. 1H). Altogether, these data suggest that VEGFR2 and VEGFC might contribute to resistance to cisplatin and erlotinib, respectively.

Tivozanib inhibits proliferation, clonogenic potential and anoikis resistance

MTT assay was carried out to determine the effect of tivozanib on proliferation of the therapy-resistant EOC cells. Treatment of these cells with tivozanib reduced their proliferation (Fig. 2A). Moreover, tivozanib diminished their clonogenic growth (Fig. 2B,C). In immortalized cells, detachment from the extracellular matrix induces anoikis, a special type of apoptosis29. Acquisition of resistance to anoikis is a prerequisite for EOC cells to survive in the ascites before forming metastatic foci30. Using an anoikis resistance assay, we found that tivozanib reduced surviving fraction of the EOC cells (Fig. 2D). Tivozanib decreased the expression of the anoikis resistance marker BCL231, suggesting that the diminished surviving fraction by tivozanib is due to enhanced anoikis (Fig. 2E).

Figure 2
Tivozanib inhibits proliferation, clonal growth and anoikis resistance.

Tivozanib induces G2/M cell cycle arrest and apoptosis

Due to the anti-proliferative effects of tivozanib, we asked if tivozanib inhibits cell cycle progression or affects apoptosis. In OVCAR3 and A2780CP cells, tivozanib increased the percentage of cells in G2/M phase while decreasing the G1/S fraction. Moreover, a small number of cells underwent apoptotic cell death, as indicated by appearance of a sub- G0/G1 population. SKOV3 cells treated with tivozanib displayed an increase in the G2/M population (Fig. 3A).

Figure 3
Tivozanib induces G2/M cell cycle arrest and apoptosis.

We next determined the effects of tivozanib on expression of genes and proteins that regulate the G2/M transition. Activation of Cdc2/cyclin B kinase complex is a pivotal step in mitotic initiation. Wee1 and myelin transcription factor 1 (encoded by MYT1) are cell cycle-regulated kinases that block mitotic entry via phosphorylation of Cdc2 while Cdc25C dephosphorylates Cdc2 and permits entry into mitosis32,33. Checkpoint kinase 2 (encoded by CHEK2) is a putative tumour suppressor that prevents mitotic progression by inhibiting Cdc25C34.

Tivozanib decreased both Cdc25C and cyclin B1 protein expression (Fig. 3B, Supplementary Fig. 2). Both mRNA and protein levels of the G2/M checkpoint regulator p21 (encoded by CDKN1A) were increased following tivozanib treatment (Fig. 3B,C, Supplementary Fig. 2). Moreover, tivozanib increased the mRNA levels of WEE1, MYT1 and CHEK2 (Fig. 3C). These data show that tivozanib inhibits proliferation of the EOC cells through a G2/M cell cycle arrest and induction of apoptosis.

Tivozanib reduces invasive abilities of the EOC cells

Interplays between the VEGF pathway and extracellular proteinases including urokinase plasminogen activator (uPA) and matrix metalloproteinases (MMPs) are implicated in peritoneal spread of EOC cells35. Evidence indicates that the VEGF/VEGFR loop drives EOC invasion through induction of uPA and MMP-236,37. Conversely, MMP-2 contributes to release of biologically active VEGFA and ascites formation38. Our findings show that tivozanib reduced enzymatic levels of uPA and MMP-2 (Fig. 4A,B, Supplementary Fig. 3).

Figure 4
(A) Tivozanib inhibits uPA activity. The cells were treated with tivozanib for 48 h and equal amounts of total secreted protein from each sample were subjected to a chromogenic substrate, which is cleaved by active uPA and produces a colorimetrically ...

The VEGF/VEGFR pathway has been shown to promote metastatic dissemination of EOC cells39,40. We next determined if tivozanib-mediated inhibition of uPA and MMP-2 associates with attenuation of migration and invasion in the EOC cells. Using Transwell assays, the resulting data demonstrate that tivozanib diminished migratory and invasive behaviour of these cells (Fig. 4C,D).

A major route for the metastatic spread of EOC cells is by attachment to the mesothelium lining in the peritoneal cavity, a critical step to establish foci and penetrate the underlying stroma41. To investigate whether tivozanib attenuates adhesive properties of the EOC cells, we assayed adhesion of tivozanib-treated cells to collagen I which is a substrate for a range of cell adhesion molecules. Tivozanib reduced adhesion of these cells to collagen I, concomitant with suppression of intercellular adhesion molecule-1 (ICAM-1) (Fig. 4E–G), a cell surface adhesion molecule that mediates tumour cell binding to the mesothelium and enhances tumour invasion42,43.

Effects of tivozanib on VEGFR2, AKT, ERK1/2 and NF-κB pathways

The VEGF/VEGFR pathway causes a cascade of downstream events including activation of Ras/MEK/ERK axis44. In ovarian carcinoma tissues, activation of STAT3 correlates with expression of VEGFA, VEGFR1 and VEGFR245. In addition, a positive association between expression of VEGFR2 and AKT activation has been demonstrated in EOC clinical samples46. Western blot analysis was applied to explore the effects of tivozanib-mediated inhibition of p-VEGFR2 on AKT, ERK1/2, STAT3 and NF-κB pathways. Tivozanib at higher doses attenuated AKT, ERK1/2 and NF-κB pathways in OVCAR3 and A2780CP cells. In comparison, tivozanib treatment induced p-ERK1/2 in SKOV3 cells, suggesting that ERK1/2 activation might be a compensatory mechanism for inhibition of VEGFR signalling in these cells (Fig. 5).

Figure 5
Effects of tivozanib on activation of pertinent oncogenic pathways.

Synergistic activity of tivozanib with EGFR-targeted therapies

EGFR overexpression occurs in 35–70% of EOC patients47. Preclinical data suggest that resistance to anti-EGFR targeted therapies results from increased tumour angiogenesis48. We therefore asked if VEGFR blockade by tivozanib increases sensitivity to EGFR-directed therapies. For the combination therapy, the cells were pre-treated with tivozanib for 4 h, followed by treatment with anti-EGFR therapies including erlotinib, gefitinib and cetuximab for 48 h. The time-sequenced tivozanib-anti-EGFR therapy had a synergistic effect on growth inhibition and activation of caspase-3, an indicator of apoptosis (Fig. 6, Table 2, Supplementary Figs 4 and 5 and Supplementary Tables 3 and 4). These data suggest that VEGFR blockade by tivozanib enhances sensitivity to the EGFR-directed therapies in the EOC cells.

Figure 6
Combined treatment with tivozanib and erlotinib results in anti-proliferative and pro-apoptotic synergism.
Table 2
Combination index (CI) and dose reduction index (DRI) of tivozanib and erlotinib combination in OVCAR3, SKOV3 and A2780CP cells.


The VEGF family is aberrantly expressed in EOC9,49. High levels of VEGFA correlate with advanced tumour stage, ascites formation, distant metastases and poor overall survival50,51. Spannuth et al have demonstrated higher expression of VEGFR2 in malignant ovarian samples compared to benign or borderline tumours, which showed a correlation with tumour grade and aggressiveness39,52. Moreover, VEGFA suppresses immune-mediated anti-tumour responses in EOC53. Although these findings indicate that the VEGF/VEGFR loop promotes malignant progression in EOC, the role of this pathway in driving the chemoresistant disease is largely unknown.

Emerging data indicate that the VEGF ligands act as survival factors for tumour cells that express the receptors54,55,56. In colorectal cancer cells, VEGFA depletion reduces cell survival and enhances chemosensitivity via blockade of AKT and ERK1/2 pathways57. An autocrine VEGFA/VEGFR2 pathway opposes apoptosis in leukaemia cells through induction of the anti-apoptotic protein Bcl-258. An angiogenic loop of VEGFC/VEGFR3 protects leukemic cells from pro-apoptotic effects of chemotherapy59 and blockade of VEGFR3 induces chemosensitisation in EOC cells60. Consistent with this, our data demonstrate that high expression of VEGFR2 and VEGFC correlates with resistance to cisplatin and erlotinib, respectively. Collectively, these findings suggest that the VEGF family plays important roles in therapy resistance and blocking all the VEGF receptors may provide advantages over single-targeted therapies.

Abnormalities in cell cycle mediators such as cyclins, cyclin-dependent kinases (CDKs) and their inhibitors are thought to be early events in the pathogenesis of EOC and provide an unchecked growth advantage61. Deregulation of the G2/M regulatory proteins p21, cyclin B1 and Cdc25C correlates with poor survival in EOC62. Exogenous expression of p21, depletion of CCNB1 and shRNA suppression of CDC25C inhibit growth and induce apoptosis63,64,65,66. These findings suggest that the cell cycle regulatory network is a promising therapeutic target to halt growth and proliferation of EOC cells67,68. In line with this, the results of the present study show that VEGFR blockade by tivozanib retards proliferation of the chemoresistant EOC cells through a G2/M cell cycle arrest via up-regulation of p21 and down-modulation of cyclin B1 and Cdc25C.

EOC is a highly metastatic malignancy characterized by peritoneal dissemination. An essential step in the peritoneal spread of EOC is adhesion and implantation of the tumour cells to the mesothelial cells lining the peritoneum69. Cell adhesion molecules including ICAM-1 mediate the adhesion process42. Moreover, extracellular proteinases MMP-2 and uPA play central roles in mesothelial invasion and their blocking reduces peritoneal metastasis70,71,72. Evidence indicates that increasing EOC migration and invasion is a mechanism through which the VEGF family promotes peritoneal dissemination73. The findings of this study reveal that tivozanib reduces adhesive and invasive characteristics of the EOC cells through inhibition of ICAM-1, uPA and MMP-2 and suggest that it might have clinical applications in translational oncology to pre-empt peritoneal dissemination.

Elevated expression of VEGFA drives resistance to anti-EGFR therapies74. Acquired resistance of xenograft models of squamous cell carcinoma to anti-EGFR monoclonal antibodies associates with enhanced levels of VEGFA48. Moreover, increased expression of VEGFA contributes to development of gefitinib-resistant colon cancer cells, which is abrogated by treatment with a VEGFR2 inhibitor75. In the present study, we found that erlotinib-resistant EOC cells exhibit over-expression of VEGFC and pre-treatment with tivozanib synergistically enhanced erlotinib anti-proliferative activity. Altogether, these data suggest that VEGFR blockade by tivozanib induce sensitisation to the EGFR-directed therapies in the EOC cells.

Members of the Bcl-2 family of proteins play an essential role in chemosensitivity in EOC76,77. High levels of Bax correlate with increased response to paclitaxel chemotherapy and reduced risk of relapse78. ABT737, a Bcl-2 family inhibitor, sensitises EOC cells to carboplatin and co-delivery of survivin shRNA and paclitaxel synergistically induces apoptosis79,80. Our findings indicate that tivozanib-induced sensitisation to the anti-EGFR therapies might be through down-regulation of the anti-apoptotic proteins survivin (encoded by BIRC5) and Bcl-2.

Taken together, our data suggest that the VEGF/VEGFR loop may have potential as a therapeutic target in the chemoresistant EOC and provide new insight into the mechanistic activities of tivozanib. Blockade of VEGF receptors by tivozanib reduced proliferative and invasive characteristics of the drug-resistant EOC cells. Combination of tivozanib with the EGFR-directed therapies displayed synergistic activity on cell growth inhibition and induction of apoptosis, suggesting that anti-VEGFR-targeted approaches induce sensitisation to the EGFR-directed therapies. Further in vivo studies are warranted to explore the anti-tumour activity of tivozanib alone or in combination with EGFR inhibitors in chemoresistant EOC.

Materials and methods

Antibodies and chemicals

Antibodies were obtained as follows: AKT, p-AKT (Ser473; clone D9E), ERK1/2 and p-ERK1/2 (Thr202/Tyr204; clone 197G2), p-VEGFR2 (Tyr1175; clone 19A10), p-NF-κB p65 (Ser536; clone 93H1) (Cell Signalling Technology); VEGFR2 (clone A-3), STAT3 (clone C-20), p-STAT3 (clone B-7), NF-κB p65 (clone C-20), ICAM-1 (clone H-108), Bcl-2 (clone N-19), Bax (clone N-20), survivin (clone FL-142), p21 (clone C-19), c-Myc (clone 9E10), cyclin B1 (clone GNS1), Wee1 (clone C-20), Cdc25C (clone C-20) and β-actin (Santa Cruz Biotechnology).

Tivozanib and apatinib (a highly selective VEGFR-2 tyrosine kinase inhibitor) were purchased from AdooQ BioScience (Irvine, CA, USA) and were dissolved in DMSO. The final concentrations of DMSO did not exceed than 0.1% [v/v] in all the treatments. Erlotinib and gefitinib (EGFR small-molecule tyrosine kinase inhibitors) were obtained from ChemieTek (Indianapolis, IN, USA). Cetuximab (a ligand-blocking anti-EGFR mAb), cisplatin and doxorubicin (DNA-damaging drugs), paclitaxel (a taxane inhibitor of microtubule disassembly), vincristine (a mitosis-blocking agent), carboplatin (an alkylating agent) and gemcitabine (a nucleoside analogue which inhibits DNA synthesis) were purchased from the pharmacy of Shariati hospital (Tehran, Iran). Poly-hydroxyethylmethacrylate polymer (poly-HEMA) was obtained from Santa Cruz Biotechnology. Human recombinant VEGFC (rVEGFC) was purchased from Peprotech.

Human ovarian carcinoma cell lines

Human ovarian carcinoma cell lines were obtained from National Cell Bank of Iran (NCBI; Tehran, Iran). These include A2780CP (adenocarcinoma), A2780S (adenocarcinoma), Caov4 (originated from metastatic fallopian tube mass), OVCAR3 (originated from ovarian cancer ascites) and SKOV3 (originated from ovarian cancer ascites)81. All the cell lines were authenticated by STR profiling using Cell IDTM system (Promega) and were routinely checked for mycoplasma infection. Cell cultures were maintained at 37 °C in 5% CO2 in a humidified incubator and cultured according to the NCBI recommendations.

Cytotoxicity assays

The EOC cells in logarithmic growth phase were plated (2 × 103 cells/well) in 96-well plates. After incubation at 37 °C for 24 h, the cultures were exposed to desired concentrations of the chemotherapeutics for 48 h and the proportion of viable cells was determined by MTT assay. Vehicle-treated cells were used as the control group. Cytotoxicity was shown as IC50 values calculated from full dose–response curves. Synergism was determined by calculation of the combination index (CI) according to Chou and Talalay82 using the CalcuSyn software (Biosoft, Cambridge, UK). CI < 1, CI = 1, and CI > 1 represent synergism, additive effects, and antagonism of the 2 drugs, respectively.

Crystal violet staining

The cells were plated at a density of 6 × 104 cells in 6-well plates and treated with the drugs for 48 h. The cultures were then washed with PBS, fixed with ice-cold methanol and stained with crystal violet (0.5% w/v). The images were acquired with an inverted microscope.

Colony formation assay

Cells were seeded into 6-well plates with a density of 200–400 cell/well. After 12 h, the cells were treated with increasing concentrations of tivozanib for 48 h. The media was changed to drug-free media and the cells were incubated at 37 °C in 5% CO2 for 10 d. The cultures were fixed in ice-cold methanol for 20 min at room temperature and stained with crystal violet solution (0.5% w/v). The colonies were counted by naked eyes and the surviving fraction (SF) was estimated as: (mean colony counts)/(cells plated) × (plating efficiency), where plating efficiency (PE) was determined as (mean colony counts)/(cells plated for controls).

Anoikis resistance assay

Poly-HEMA was solubilized in 95% ethanol (20 mg/mL) and then 25 μL of this solution was placed in 96-well plates and dried in a tissue culture hood. Anoikis was induced by culturing 5 × 103 cells on poly-HEMA coated plates in the medium containing increasing concentrations of tivozanib. The cell suspension cultures were maintained in a humidified 5% CO2 incubator at 37 °C for 48 h. One hundred μL of MTT solution (0.5 mg/mL) was added to each well and the cells were further incubated at 37 °C for 2 h. The precipitated formazan was dissolved in DMSO and the optical densitometry was measured at 570 nm.

Analysis of gene expression by quantitative reverse transcription-PCR

The quantitative reverse transcription-PCR (qRT-PCR) analysis was performed on a StepOne Plus instrument (Applied Biosystems) using RealQ-PCR Master Mix kit (Ampliqon, Copenhagen, Denmark). Thermal cycling conditions involved an activation step for 15 min at 95 °C followed by 40 cycles including a denaturation step for 15 s at 95 °C and a combined annealing/extension step for 1 min at 60 °C. The primers used are listed in Supplementary Table 2. The target gene expression levels were normalized to hypoxanthine phosphoribosyl transferase1 (HPRT1) levels in the same reaction. For calculations, 2 –ΔΔC T formula was used, with ΔΔCT = (CT Target − CT HPRT1) experimental sample − (CT Target – CT HPRT1) control samples, where CT is cycle threshold.

Western blot analysis

Total protein extracts were prepared in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease and phosphatase inhibitors (Roche Molecular Biochemicals) for 30 min at 4 °C. Fifty to hundred μg of lysate was resolved by SDS-PAGE, transferred to PVDF membrane (Membrane Solutions, TX, USA) then probed with primary and horseradish peroxidase (HRP)-conjugated secondary antibodies (Sigma). β-actin was used as the loading control and proteins were detected using a BM chemiluminescence detection kit (Roche Molecular Biochemicals).

Cell cycle analysis

Propidium iodide staining was conducted for detection of DNA content. Following tivozanib treatment for 48 h, harvested cells were washed in ice-cold PBS, fixed in 70% ethanol and stored at −20 °C overnight. Vehicle-treated cells were used as the control group. The cell pellets were then incubated with RNase A (100 μg/mL) (Sigma), propidium iodide (50 μg/mL) (Sigma) and 0.05% Triton X-100. Cellular DNA content was analyzed on a FACSCalibur (BD Bioscience) flow cytometer equipped with CellQuest Pro software.


Equal amounts of secreted protein from the conditioned media of tivozanib-treated and vehicle-treated cells were applied to 10% polyacrylamide gels copolymerized with 1 mg/mL gelatin A (Sigma). After electrophoresis, gels were rinsed in 2.5% Triton X-100 (2 × 15 min) to remove SDS, followed by incubation at 37 °C overnight in incubation buffer (0.15 M NaCl, 10 mM CaCl2, 0.02% NaN3 in 50 mM Tris-HCl, pH 7.5). The gels were then stained (0.5% Coomassie Brilliant Blue) and destained with 7% methanol and 5% acetic acid. Areas of enzymatic activity appeared as clear bands over the dark background.

Urokinase-type plasminogen activator activity assay

Urokinase-type plasminogen activator (uPA) activity was assayed with a uPA-specific chromogenic substrate according to the manufacturer’s instructions (Millipore). Equal amounts of protein from the uPA-containing conditioned media were added to the chromogenic substrate and incubated at 37 °C for 1 h. The samples were then read at 405 nm.

Cell adhesion

After treatment with tivozanib for 48 h, the cells were counted and equal cell number from both tivozanib-treated and vehicle-treated groups was seeded in collagen I-coated 60 mm dishes (Biocoat Cell Environments; Becton Dickinson). Following incubation for 15 min at 37 °C, the cells were washed twice with cold PBS, stained with 0.5% crystal violet, lysed with 30% acetic acid and the optical densitometry was measured at 590 nm.

Transwell cell migration and invasion

Cell migration and invasion assays were carried out as described earlier83.

Caspase 3 activity assay

To assess induction of apoptosis, a colorimetric caspase 3 activity assay was employed according to the manufacturer’s protocol (Sigma). Briefly, cell lysates from both adherent and floating cells were centrifuged at 20000 × g for 10 min. Twenty μg of the supernatant was incubated with 85 μL of assay buffer plus 10 μL of caspase 3 substrate acetyl-Asp- Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) in a 96-well plate at 37 °C for 12 h. The samples were then read at 405 nm in an ELISA reader.

Statistical analysis

All data were evaluated in triplicate against vehicle-treated control cells and collected from three independent experiments. Data were graphed and analysed using GraphPad Prism Software 6.0 using one-way ANOVA and the unpaired two-tailed Student’s t test. All data are presented as mean ± standard deviation (SD).

Additional Information

How to cite this article: Momeny, M. et al. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci. Rep. 7, 45954; doi: 10.1038/srep45954 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information:


Research reported in this publication was supported by Elite Researcher Grant Committee under award number [943594] from National Institute for Medical Research Development (NIMAD), Tehran, Iran and also a grant from Haematology/oncology and Stem Cell Transplantation Research Centre, Shariati hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Technical assistance of Ms. Roghieh Koohi Ortakand is acknowledged.


The authors declare no competing financial interests.

Author Contributions M.M. designed the research; M.M., Z.S., G.Z., F.M., H.E., H.Y., S.M., E.M.P. and F.B. conducted the research; M.M., A.P., L.D., D.B., M.G., S.M.T., A.R.D., M.Y., K.A. and A.G. analysed the data; M.M. wrote the paper; S.H.G. had primary responsibility for the final content. All authors have reviewed and approved the final manuscript.


  • Siegel R. L., Miller K. D. & Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7–30 (2016). [PubMed]
  • Korkmaz T., Seber S. & Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. Critical reviews in oncology/hematology 98, 180–188 (2016). [PubMed]
  • Dinh P., Harnett P., Piccart-Gebhart M. J. & Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Critical reviews in oncology/hematology 67, 103–112, doi: (2008).10.1016/j.critrevonc.2008.01.012 [PubMed] [Cross Ref]
  • Ferrandina G. et al. . Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, 890–896, doi: (2008).10.1200/JCO.2007.13.6606 [PubMed] [Cross Ref]
  • Hicklin D. J. & Ellis L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23, 1011–1027, doi: (2005).10.1200/JCO.2005.06.081 [PubMed] [Cross Ref]
  • Spannuth W. A., Sood A. K. & Coleman R. L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5, 194–204, doi: (2008).10.1038/ncponc1051 [PubMed] [Cross Ref]
  • Vecchione A. et al. . A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 110, 9845–9850, doi: (2013).10.1073/pnas.1305472110 [PubMed] [Cross Ref]
  • Santulli G. et al. . In vivo properties of the proangiogenic peptide QK. J Transl Med 7, 41, doi: (2009).10.1186/1479-5876-7-41 [PMC free article] [PubMed] [Cross Ref]
  • Boocock C. A. et al. . Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian Carcinoma. Journal of the National Cancer Institute 87, 506–516 (1995). [PubMed]
  • Decio A. et al. . Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol 184, 1050–1061, doi: (2014).10.1016/j.ajpath.2013.12.030 [PubMed] [Cross Ref]
  • Olson T. A., Mohanraj D., Carson L. F. & Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer research 54, 276–280 (1994). [PubMed]
  • Nishida N. et al. . Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101, 1364–1374 (2004). [PubMed]
  • Fagotti A. et al. . Peritoneal carcinosis of ovarian origin. World J Gastrointest Oncol 2, 102–108 (2010). [PMC free article] [PubMed]
  • Mesiano S., Ferrara N. & Jaffe R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. The American journal of pathology 153, 1249–1256 (1998). [PubMed]
  • Monk B. J., Dalton H., Farley J. H., Chase D. M. & Benjamin I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Critical reviews in oncology/hematology 86, 161–175 (2013). [PubMed]
  • Eskander R. N. & Tewari K. S. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecologic oncology 132, 496–505 (2014). [PubMed]
  • McLachlan J., Lima J. P., Dumas L. & Banerjee S. Targeted agents and combinations in ovarian cancer: where are we now? Expert Rev Anticancer Ther 16, 441–454, doi: (2016).10.1586/14737140.2016.1162101 [PubMed] [Cross Ref]
  • Perren T. J. et al. . A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 365, 2484–2496 (2011). [PubMed]
  • Burger R. A. et al. . Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 365, 2473–2483 (2011). [PubMed]
  • Pujade-Lauraine E. et al. . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Journal of Clinical Oncology 32, 1302–1308 (2014). [PubMed]
  • Burger R. A., Sill M. W., Monk B. J., Greer B. E. & Sorosky J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25, 5165–5171, doi: (2007).10.1200/JCO.2007.11.5345 [PubMed] [Cross Ref]
  • Graybill W., Sood A. K., Monk B. J. & Coleman R. L. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic oncology 138, 223–226, doi: (2015).10.1016/j.ygyno.2015.07.008 [PubMed] [Cross Ref]
  • De Luca A. & Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs: the investigational drugs journal 13, 636–645 (2010). [PubMed]
  • Jayson G. C., Kohn E. C., Kitchener H. C. & Ledermann J. A. Ovarian cancer. The Lancet 384, 1376–1388 (2014). [PubMed]
  • Marchetti C. et al. . First-line treatment of advanced ovarian cancer: current research and perspectives. Expert review of anticancer therapy 10, 47–60 (2010). [PubMed]
  • Eskens F. A. et al. . Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clinical Cancer Research 17, 7156–7163 (2011). [PubMed]
  • Marchetti C. et al. . Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. Cancer treatment reviews 42, 41–46 (2016). [PubMed]
  • Lee M. J. et al. . Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780–794 (2012). [PMC free article] [PubMed]
  • Frisch S. M. & Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 9, 701–706 (1997). [PubMed]
  • Sher I., Adham S. A., Petrik J. & Coomber B. L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. International journal of cancer. Journal international du cancer 124, 553–561, doi: (2009).10.1002/ijc.23963 [PubMed] [Cross Ref]
  • Trapp E. K. et al. . Abstract P4-01-16: Detection of EMT, anoikis and stem cell markers in metastatic breast cancer patients under different lines of treatment. Cancer research 75, P4-01-16–P04-01-16 (2015).
  • Chow J. P. H. & Poon R. Y. C. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 32, 4778–4788 (2013). [PubMed]
  • Boutros R., Lobjois V. & Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Reviews Cancer 7, 495–507 (2007). [PubMed]
  • Antoni L., Sodha N., Collins I. & Garrett M. D. CHK2 kinase: cancer susceptibility and cancer therapy–two sides of the same coin? Nature Reviews Cancer 7, 925–936 (2007). [PubMed]
  • Graves L. E. et al. . Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer research 64, 7045–7049 (2004). [PubMed]
  • Zhang A. et al. . Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncology reports 15, 831–836 (2006). [PubMed]
  • So J., Wang F.-q., Navari J., Schreher J. & Fishman D. A. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecologic oncology 97, 870–878 (2005). [PubMed]
  • Belotti D. et al. . Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells implications for ascites formation. Cancer research 63, 5224–5229 (2003). [PubMed]
  • Wang F.-q., Barfield E., Dutta S., Pua T. & Fishman D. A. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecologic oncology 115, 414–423 (2009). [PubMed]
  • Huang K.-J. & Sui L.-H. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Medical oncology 29, 318–323 (2012). [PubMed]
  • Slack-Davis J. K., Atkins K. A., Harrer C., Hershey E. D. & Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer research 69, 1469–1476 (2009). [PubMed]
  • Gardner M. J., Jones L. M., Catterall J. B. & Turner G. A. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer letters 91, 229–234 (1995). [PubMed]
  • Roland C. L., Harken A. H., Sarr M. G. & Barnett C. C. ICAM-1 expression determines malignant potential of cancer. Surgery 141, 705–707 (2007). [PubMed]
  • Mason J. C. et al. . Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)-and Protein Kinase C-α/ϵ (PKCα/ϵ)-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A. Journal of Biological Chemistry 279, 41611–41618 (2004). [PubMed]
  • Chen H., Ye D., Xie X., Chen B. & Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecologic oncology 94, 630–635 (2004). [PubMed]
  • Trinh X. B. et al. . The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British journal of cancer 100, 971–978 (2009). [PMC free article] [PubMed]
  • Fischer-Colbrie J. et al. . EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer research 17, 613–619 (1996). [PubMed]
  • Viloria-Petit A. et al. . Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo A role for altered tumor angiogenesis. Cancer research 61, 5090–5101 (2001). [PubMed]
  • Inan S. et al. . Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta’s in epithelial ovarian tumors. Histol Histopathol 21, 1055–1064 (2006). [PubMed]
  • Rudlowski C. et al. . Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long‐term follow‐up. International Journal of Gynecological Cancer 16, 183–189 (2006). [PubMed]
  • Yu L., Deng L., Li J., Zhang Y. & Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology 128, 391–396 (2013). [PubMed]
  • Spannuth W. A. et al. . Functional significance of VEGFR‐2 on ovarian cancer cells. International journal of cancer 124, 1045–1053 (2009). [PMC free article] [PubMed]
  • Tiper I. V. et al. . VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 22, 4249–4258, doi: (2016).10.1158/1078-0432.CCR-15-2518 [PMC free article] [PubMed] [Cross Ref]
  • Calvani M., Trisciuoglio D., Bergamaschi C., Shoemaker R. H. & Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer research 68, 285–291 (2008). [PubMed]
  • Pidgeon G. P., Barr M. P., Harmey J. H., Foley D. A. & Bouchier-Hayes D. J. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. British journal of cancer 85, 273–278, doi: (2001).10.1054/bjoc.2001.1876 [PMC free article] [PubMed] [Cross Ref]
  • Hua K.-T. et al. . Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843, 387–397 (2014). [PubMed]
  • Bhattacharya R. et al. . Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer research 76, 3014–3024, doi: (2016).10.1158/0008-5472.CAN-15-1605 [PMC free article] [PubMed] [Cross Ref]
  • Dias S., Shmelkov S. V., Lam G. & Rafii S. VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99, 2532–2540 (2002). [PubMed]
  • Dias S., Choy M., Alitalo K. & Rafii S. Vascular endothelial growth factor (VEGF)–C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99, 2179–2184 (2002). [PubMed]
  • Lim J., Yang K., Taylor-Harding B., Wiedemeyer W. R. & Buckanovich R. J. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia 16, 343–353. e342 (2014). [PMC free article] [PubMed]
  • Landen C. N., Birrer M. J. & Sood A. K. Early events in the pathogenesis of epithelial ovarian cancer. Journal of Clinical Oncology 26, 995–1005 (2008). [PubMed]
  • Hashiguchi Y. et al. . Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Human pathology 35, 165–175 (2004). [PubMed]
  • Crombez L. et al. . Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic acids research 37, 4559–4569, doi: (2009).10.1093/nar/gkp451 [PMC free article] [PubMed] [Cross Ref]
  • Davies S. et al. . High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 33, 402–410, doi: (2014).10.1097/PGP.0000000000000081 [PMC free article] [PubMed] [Cross Ref]
  • Qin L. F. & Ng I. O. Exogenous expression of p21 WAF1/CIP1 exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer letters 172, 7–15 (2001). [PubMed]
  • Wei S. et al. . A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences 106, 12974–12979 (2009). [PubMed]
  • Ye Q., Lei L. & Aili A. Identification of potential targets for ovarian cancer treatment by systematic bioinformatics analysis. European journal of gynaecological oncology 36, 283–289 (2014). [PubMed]
  • Urzua U., Ampuero S., Roby K. F., Owens G. A. & Munroe D. J. Dysregulation of mitotic machinery genes precedes genome instability during spontaneous pre-malignant transformation of mouse ovarian surface epithelial cells. BMC Genomics 17, 728, doi: (2016).10.1186/s12864-016-3068-5 [PMC free article] [PubMed] [Cross Ref]
  • Lengyel E. Ovarian cancer development and metastasis. The American journal of pathology 177, 1053–1064 (2010). [PubMed]
  • Kenny H. A., Kaur S., Coussens L. M. & Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of clinical investigation 118, 1367–1379 (2008). [PubMed]
  • Kenny H. A. & Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell cycle 8, 683–688 (2009). [PMC free article] [PubMed]
  • Wilhelm O., Schmitt M., Höhl S., Senekowitsch R. & Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clinical & experimental metastasis 13, 296–302 (1995). [PubMed]
  • Moghaddam S. M., Amini A., Morris D. L. & Pourgholami M. H. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer and Metastasis Reviews 31, 143–162 (2012). [PMC free article] [PubMed]
  • Vallböhmer D. et al. . Molecular determinants of cetuximab efficacy. Journal of Clinical Oncology 23, 3536–3544 (2005). [PubMed]
  • Ciardiello F. et al. . Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clinical Cancer Research 10, 784–793 (2004). [PubMed]
  • Eliopoulos A. G. et al. . The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11, 1217–1228 (1995). [PubMed]
  • Beale P. J., Rogers P., Boxall F., Sharp S. Y. & Kelland L. R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. British journal of cancer 82, 436–440, doi: (2000).10.1054/bjoc.1999.0939 [PMC free article] [PubMed] [Cross Ref]
  • Tai Y. T. et al. . BAX protein expression and clinical outcome in epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 16, 2583–2590 (1998). [PubMed]
  • Witham J. et al. . The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clinical cancer research : an official journal of the American Association for Cancer Research 13, 7191–7198, doi: (2007).10.1158/1078-0432.CCR-07-0362 [PubMed] [Cross Ref]
  • Hu Q. et al. . Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 33, 6580–6591 (2012). [PubMed]
  • Jacob F., Nixdorf S., Hacker N. F. & Heinzelmann-Schwarz V. A. Reliable in vitro studies require appropriate ovarian cancer cell lines. Journal of ovarian research 7, 60, doi: (2014).10.1186/1757-2215-7-60 [PMC free article] [PubMed] [Cross Ref]
  • Chou T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research 70, 440–446, doi: (2010).10.1158/0008-5472.CAN-09-1947 [PubMed] [Cross Ref]
  • Momeny M. et al. . Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget 6, 3932–3946, doi: (2015).10.18632/oncotarget.2846 [PMC free article] [PubMed] [Cross Ref]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group